Next Article in Journal
Development of New Antimycobacterial Sulfonyl Hydrazones and 4-Methyl-1,2,3-thiadiazole-Based Hydrazone Derivatives
Previous Article in Journal
Surgical Antimicrobial Prophylaxis in Patients of Neonatal and Pediatric Age Subjected to Eye Surgery: A RAND/UCLA Appropriateness Method Consensus Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibiotics
Volume 11
Issue 5
10.3390/antibiotics11050563
antibiotics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

A Multicentre, Prospective, and Retrospective Registry to Characterize the Use, Effectiveness, and Safety of Dalbavancin in German Clinical Practice

by
Frank Hanses
1,2,
Sebastian Dolff
3,
Janina Trauth
4,
Michael Seimetz
5 and
Stefan Hagel
6,*
1
Emergency Department, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany
2
Department for Infectious Diseases and Infection Control, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany
3
Department of Infectious Diseases, West German Centre of Infectious Diseases, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 55, 45122 Essen, Germany
4
Division of Infectious Diseases, Department of Internal Medicine II, University Hospital Giessen and Marburg, Klinikstraße 33, 35392 Giessen, Germany
5
Advanz Pharma Germany GmbH, Herforder Str. 69, 33602 Bielefeld, Germany
6
Institute for Infectious Diseases and Infection Control, Jena University Hospital—Friedrich Schiller University Jena, Am Klinikum 1, 07747 Jena, Germany
*
Author to whom correspondence should be addressed.
Antibiotics 2022, 11(5), 563; https://doi.org/10.3390/antibiotics11050563
Submission received: 14 March 2022 / Revised: 19 April 2022 / Accepted: 20 April 2022 / Published: 22 April 2022
Review Reports Versions Notes

Abstract

The antibiotic dalbavancin is approved for intravenous treatment of adults with acute bacterial skin and skin structure infections. This study aimed to observe the use, effectiveness, and safety of dalbavancin in clinical practice in Germany. It was a multicentre, prospective, and retrospective registry and consecutively enrolled patients treated with dalbavancin. Each patient was observed from the first to the last dose of dalbavancin, with a 30-day follow-up. Patient inclusion was planned for 2 years, but was terminated early due to low recruitment. All analyses were descriptive. Between November 2018 and December 2019, nine patients were enrolled. Only three patients were treated for the approved indication. Outcome was assessed by the physicians as ‘success’ in five (55.6%) patients, ‘failure’ in one (11.1%) patient, and non-evaluable in three (33.3%) patients. Although the success rate of dalbavancin was lower than reported previously, this may be due to the severity of underlying infections and patients’ high Charlson Comorbidity Index. None of the two reported adverse events were considered related to dalbavancin. These findings were in line with real-world data for dalbavancin from other countries, supporting the drug’s positive benefit–risk profile and suggesting frequent off-label use in German routine practice.
Keywords: dalbavancin; registry; acute bacterial skin and skin structure infection (ABSSSI); real-world setting dalbavancin; registry; acute bacterial skin and skin structure infection (ABSSSI); real-world setting

Share and Cite

MDPI and ACS Style

Hanses, F.; Dolff, S.; Trauth, J.; Seimetz, M.; Hagel, S. A Multicentre, Prospective, and Retrospective Registry to Characterize the Use, Effectiveness, and Safety of Dalbavancin in German Clinical Practice. Antibiotics 2022, 11, 563. https://doi.org/10.3390/antibiotics11050563

AMA Style

Hanses F, Dolff S, Trauth J, Seimetz M, Hagel S. A Multicentre, Prospective, and Retrospective Registry to Characterize the Use, Effectiveness, and Safety of Dalbavancin in German Clinical Practice. Antibiotics. 2022; 11(5):563. https://doi.org/10.3390/antibiotics11050563

Chicago/Turabian Style

Hanses, Frank, Sebastian Dolff, Janina Trauth, Michael Seimetz, and Stefan Hagel. 2022. "A Multicentre, Prospective, and Retrospective Registry to Characterize the Use, Effectiveness, and Safety of Dalbavancin in German Clinical Practice" Antibiotics 11, no. 5: 563. https://doi.org/10.3390/antibiotics11050563

APA Style

Hanses, F., Dolff, S., Trauth, J., Seimetz, M., & Hagel, S. (2022). A Multicentre, Prospective, and Retrospective Registry to Characterize the Use, Effectiveness, and Safety of Dalbavancin in German Clinical Practice. Antibiotics, 11(5), 563. https://doi.org/10.3390/antibiotics11050563

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop